SYRE SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 3, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 4, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 5, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Feb 19, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 4, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 5, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Spyre Therapeutics Reports Q3 2026 Financial Results and Corporate Pipeline Updates

Nov 3, 2026

8-K

Spyre Therapeutics Announces Pricing of $350 Million Common Stock Offering

Oct 7, 2026

8-K

Spyre Announces Potential Best-in-Class SPY003 (anti-IL-23) Part A Induction Results from SKYLINE Trial, Completing Proof-of-Concept for All Three Components of

Sep 8, 2026

8-K

Spyre Therapeutics Announces Topline Results from the Rheumatoid Arthritis Sub-study of the SKYWAY Phase 2 Trial of SPY072

Aug 25, 2026

8-K

Spyre Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Update

Aug 4, 2026

8-K

Spyre Therapeutics Announces Positive Phase 2 SKYLINE Trial Results for SPY002 in Ulcerative Colitis

Jun 15, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

REGISTERED OFFERING

Oct 6, 2026

424B5

PENDING FIXED PRICE OFFERING | Bank: Jefferies

Oct 5, 2026

424B5

FIXED PRICE OFFERING | Offering amount: $403,000,000 | Shares: 6,500,000 | Price: $62.000 | Bank: Jefferies, Goldman Sachs & Co. LLC, Evercore ISI, Guggenheim Securities, LifeSci Capital

Apr 15, 2026

424B5

PENDING FIXED PRICE OFFERING | Offering amount: $300,000,000 | Bank: Jefferies, Goldman Sachs & Co. LLC, Evercore ISI, Guggenheim Securities

Apr 13, 2026

424B5

REGISTERED OFFERING

Oct 14, 2025

424B5

PENDING FIXED PRICE OFFERING | Bank: Jefferies, TD Cowen, Leerink Partners, Stifel, Wedbush, PacGrow

Oct 14, 2025

Registrations

TYPE

HEADLINE

FILED AT

S-3ASR

June 2026 SHELF + ATM

Jun 26, 2026

POS AM

Form POS AM - Post-Effective amendments for registration statement

Feb 27, 2026

S-3

Form S-3 - Registration statement under Securities Act of 1933

Feb 19, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Feb 19, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Aug 5, 2025

POS AM

Form POS AM - Post-Effective amendments for registration statement

Mar 7, 2025

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 10, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 10, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 14, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 14, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 1, 2024

PRE 14A

Form PRE 14A - Other preliminary proxy statements

Mar 20, 2024

Ownerships

TYPE

HEADLINE

FILED AT

SCHEDULE 13D/A

Fairmount Funds Management LLC (Filed by)

Oct 9, 2026

King-Jones Heidy (Reporting)

Oct 2, 2026

Turtle Cameron (Reporting)

Oct 2, 2026

Burrows Scott L (Reporting)

Oct 2, 2026

144

Form 144 - Report of proposed sale of securities

Oct 1, 2026

144

Form 144 - Report of proposed sale of securities

Oct 1, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Mar 5, 2026

EFFECT

Form EFFECT - Notice of Effectiveness

Mar 2, 2026

CORRESP

Form CORRESP - Correspondence

Feb 25, 2026

LETTER

Form UPLOAD - SEC-generated letter

Feb 25, 2026

LETTER

Form UPLOAD - SEC-generated letter

Jun 2, 2025

CORRESP

Form CORRESP - Correspondence

May 21, 2025

Spyre Therapeutics, Inc. SYRE · SEC Filings